Re-feeding Gastric Residuals in Preterm Infants
Re-feeding Residuals Versus Feeding Fresh Formula/Milk for Feeding Intolerance in Premature Infants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35249
- University of Alabama at Birmingham
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Gestational age between 23.0 and 28.6 weeks;
- Receiving intravenous fluids but not enteral nutrition more than trophic feeds;
- Written informed consent from the parents
Exclusion Criteria:
- Major congenital/chromosomal anomalies;
- Moribund infant with low likelihood of survival, in the opinion of the clinical team
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Re-feeding gastric residuals
In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance.
This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
|
In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance.
This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
|
|
Active Comparator: Fresh feeding breastmilk/formula only
In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be discarded and fresh breast milk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance.
This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
|
In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be discarded and fresh breastmilk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance.
This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to establish full enteral feeding
Time Frame: Birth to 28 days
|
Time required to reach enteral feeding at 120cc/kg/day
|
Birth to 28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feeding intolerance
Time Frame: Birth to 28 days
|
Feeding intolerance defined as interruption or cessation of enteral feeds for a perod greater than 12 hours for presence of bloody gastric residuals or an abnormal abdominal examination.
|
Birth to 28 days
|
|
Episodes of feeding intolerance resulting in a interruption or cessation of progression of enteral feeds for a period of < 12 hours.
Time Frame: Birth to 28 days
|
Number of episodes of feeding intolerance resulting in an interruption or cessation of progression of enteral feedings for a period of < 12 hours.
|
Birth to 28 days
|
|
Number of days receiving parenteral nutrition
Time Frame: Birth to 28 days
|
Total number of days or partial day receiving parenteral nutrition
|
Birth to 28 days
|
|
Duration of hospital stay
Time Frame: Birth to 120 days or discharge, whichever occurs first.
|
Length of hospital stay in days
|
Birth to 120 days or discharge, whichever occurs first.
|
|
Diagnosis of necrotizing enterocolitis
Time Frame: Birth to 120 days or discharge, whichever occurs first.
|
Diagnosis of necrotizing enterocolitis, Bell's Staging II-IV
|
Birth to 120 days or discharge, whichever occurs first.
|
|
Diagnosis of intestinal perforation
Time Frame: Birth to 120 days or discharge, whichever occurs first
|
Diagnosis of intestinal perforation between birth and 120 days or discharge, whichever occurs first.
|
Birth to 120 days or discharge, whichever occurs first
|
|
Death
Time Frame: Birth to 120 days
|
Death prior to 121 days of age.
|
Birth to 120 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ariel A Salas, MD, University of Alabama at Birmingham
- Study Director: Namasivayam Ambalavanan, MD, University of Alabama at Birmingham
- Study Chair: Waldemar A Carlo, MD, University of Alabama at Birmingham
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UAB Neo 004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.